Anakinra

Anakinra has been studied in 14 papers since 2019: 2 trials and 1 observational study in people, 6 in animals, 1 in cells, 4 reviews; 5 in the past year. It is an approved medicine. The newest story, Oct 2, 2026: “ASXL1-mutant clonal hematopoiesis links to aortic valve disease”.

InterventionApproved 2001

14 papers study it17 findingsUpdated

See all 13 papers on anakinra

At a glance

Independent labs found the same change in people. 9 independent labs in 6 countries; 123 trials, none about aging, 42 with no results posted.

“The linear mixed-effects model controlling for baseline covariates revealed that peak VO2 was significantly higher post-intervention compared with pre-intervention (F(1,52.2)=6.05, p=0.02).”
The Effects of Anakinra on Cardiorespiratory Fitness in Heart Failure Stratified by Age in Phase II Clinical TrialsJournal of cardiovascular pharmacology2025doi:10.1097/fjc.0000000000001756

1 of its findings points the other way.

Humans: replicated by independent labs. Cells and mice: a single group. Worms or flies: nothing yet.
  • 9 independent labs in 6 countries
  • 1 finding against
  • 123 trials, none about aging, 42 with no results posted
  • Funders: National Institutes of Health and others
  • 8 of 16 findings with company ties
  • 20 of 123 trials sponsored by its developers
  • Human trial2
  • Humans1
  • Animals6
  • Cells1

Studies in people

2 studies gave anakinra to people and measured what changed.

What changedDesignPeopleSource

down: Decreases C-reactive proteinP = 0.030

down: Decreases total leukocyte countP < 0.001

up: Increases GLP-1P = 0.020

Randomized trialovernightPrediabetesAmerican journal of physiology. Endocrinology and metabolism, Mar 4, 2026

up: Improves cardiorespiratory fitness

down: Decreases C-reactive protein−3.6 [−8.1 to −1.9] mg/L vs −2.7 [−9.0 to −1.4] mg/L

Trial4 [2-12] weeks73 peopleBothstratified <60 years and ≥60 yearsHF patientsJournal of cardiovascular pharmacology, Sep 9, 2025

What did studies of anakinra find?

14

Studies of anakinra measured 14 outcomes, among them C-reactive protein, cardiorespiratory fitness and valvular calcification.

C-reactive protein

downin humans2

2 studies
  1. Anakinra decreases C-reactive protein in humans (prediabetes) (P = 0.030).

    “Two injections of anakinra significantly reduced total leucocyte count (P < 0.001), neutrophils (P < 0.001), monocytes (P = 0.006), and CRP (P = 0.030) compared with placebo.”

    Human trialprediabetesovernight

    Acute interleukin-1β antagonism decreases systemic inflammation, increases GLP-1 release, and modulates insulin secretion in individuals with prediabetes

    American journal of physiology. Endocrinology and metabolism

  2. Anakinra decreases C-reactive protein in humans (−3.6 [−8.1 to −1.9] mg/L vs −2.7 [−9.0 to −1.4] mg/L).

    “Anakinra significantly decreased hsCRP in both groups, with a similar change in both age groups (<60 years: −3.6 [−8.1 to −1.9] mg/L; ≥60 years: −2.7 [−9.0 to −1.4] mg/L; p=0.49; ).”

    Human trial4 [2-12] weeksn = 73

    The Effects of Anakinra on Cardiorespiratory Fitness in Heart Failure Stratified by Age in Phase II Clinical Trials

    Journal of cardiovascular pharmacology

  3. Anakinra decreases C-reactive protein in humans (heart failure) (-3.6 (-8.1 to -1.9) mg/L, P < 0.001).

    “In both groups, anakinra decreased hsCRP [<60 years: -3.6 (-8.1 to -1.9) mg/L; P < 0.001”

    Human trialheart failuresubcutaneous100 mg dailymedian of 4 weeksn = 49

    The Effects of Anakinra on Cardiorespiratory Fitness in Heart Failure Stratified by Age in Phase II Clinical Trials

    Journal of cardiovascular pharmacology

More on C-reactive protein

Cardiorespiratory fitness

upin humans1

1 study
  1. Anakinra improves cardiorespiratory fitness in humans.

    “The linear mixed-effects model controlling for baseline covariates revealed that peak VO2 was significantly higher post-intervention compared with pre-intervention (F(1,52.2)=6.05, p=0.02).”

    Human trial4 [2-12] weeksn = 73

    The Effects of Anakinra on Cardiorespiratory Fitness in Heart Failure Stratified by Age in Phase II Clinical Trials

    Journal of cardiovascular pharmacology

  2. Anakinra improves cardiorespiratory fitness in humans (heart failure) (+0.5 (-0.9 to 2.5) mL·kg -1 ·minute -1, P = 0.036).

    “increased peak VO 2peak [<60 years: +0.5 (-0.9 to 2.5) mL·kg -1 ·minute -1 ; P = 0.036”

    Human trialheart failuresubcutaneous100 mg dailymedian of 4 weeksn = 49

    The Effects of Anakinra on Cardiorespiratory Fitness in Heart Failure Stratified by Age in Phase II Clinical Trials

    Journal of cardiovascular pharmacology

Valvular calcification

downin human cells1

1 study
  1. Anakinra decreases valvular calcification in human VICs treated with ASXL1 mutant macrophage conditioned media.

    “Accelerated VIC calcification was reduced by IL-1 inhibition by anakinra or IL-6 inhibition by tocilizumab.”

    Cellsin human VICs treated with ASXL1 mutant macrophage conditioned media

    ASXL1-mutant clonal hematopoiesis links to aortic valve disease

    medRxivPreprint

Inflammation

downin reviews1

1 study
  1. Anakinra decreases inflammation (osteoarthritis).

    “Small molecules such as anakinra, metformin, and rapamycin show potential in reducing inflammation and preserving cartilage”

    Reviewosteoarthritiscartilage

    Inflammaging and osteoarthritis - therapeutic opportunities

    Frontiers in immunology

More on Inflammation

NLRP3 inflammasome activation

downin human cells1

1 study
  1. Anakinra prevents NLRP3 inflammasome activation in IL-1β-stimulated cells.

    “blockade of IL-1R with anakinra prevented inflammasome activation, metabolic reprogramming and sEV release.”

    Cellsin IL-1β-stimulated cellsaortic smooth muscle cell

    Anakinra prevents high glucose-mediated potentiation of IL-1β-induced NLRP3 inflammasome activation, small extracellular vesicle release and vascular inflammation

    Biochemical pharmacology

Glucagon

upin humans1

1 study
  1. Anakinra increases glucagon in humans (mixed meal tolerance test in prediabetes) (P = 0.003).

    “with GLP-1 (P = 0.020) and glucagon (P = 0.003) levels being significantly higher at 120 min under anakinra.”

    Human trialmixed meal tolerance test in prediabetes120 min

    Acute interleukin-1β antagonism decreases systemic inflammation, increases GLP-1 release, and modulates insulin secretion in individuals with prediabetes

    American journal of physiology. Endocrinology and metabolism

More on Glucagon

GLP-1

upin humans1

1 study
  1. Anakinra increases GLP-1 in humans (mixed meal tolerance test in prediabetes) (P = 0.020).

    “with GLP-1 (P = 0.020) and glucagon (P = 0.003) levels being significantly higher at 120 min under anakinra.”

    Human trialmixed meal tolerance test in prediabetes120 min

    Acute interleukin-1β antagonism decreases systemic inflammation, increases GLP-1 release, and modulates insulin secretion in individuals with prediabetes

    American journal of physiology. Endocrinology and metabolism

More on GLP-1

Total leukocyte count

downin humans1

1 study
  1. Anakinra decreases total leukocyte count in humans (prediabetes) (P < 0.001).

    “Two injections of anakinra significantly reduced total leucocyte count (P < 0.001), neutrophils (P < 0.001), monocytes (P = 0.006), and CRP (P = 0.030) compared with placebo.”

    Human trialprediabetesovernight

    Acute interleukin-1β antagonism decreases systemic inflammation, increases GLP-1 release, and modulates insulin secretion in individuals with prediabetes

    American journal of physiology. Endocrinology and metabolism

More on Total leukocyte count

PC1/3 downregulation

downin mouse cells1

1 study
  1. Anakinra prevents PC1/3 downregulation in mouse cells (IL-1β-treated islets; pharmacological IL-1 inhibition or β-cell IL-1 receptor knockout).

    “Pharmacological inhibition of IL-1 signaling or genetic ablation of the IL-1 receptor in β-cells effectively prevented IL-1β-mediated downregulation of PC1/3”

    CellsIL-1β-treated islets; pharmacological IL-1 inhibition or β-cell IL-1 receptor knockoutpancreatic islet

    IL-1 and IL-6 Impair Proinsulin Maturation in Aging Mice via Downregulation of Prohormone Convertases

    ADA Scientific Sessions 2025 abstract

More on PC1/3 downregulation

Polyclonal output

upin cells1

1 study
  1. Anakinra increases polyclonal output in cells (HDR-edited cells).

    “treatment with Anakinra, an IL-1 signaling antagonist, as a promising strategy to enhance polyclonal output in HDR-edited cells”

    CellsHDR-edited cellshematopoietic stem and progenitor cells

    Senescence and inflammation are unintended adverse consequences of CRISPR-Cas9/AAV6-mediated gene editing in hematopoietic stem cells

    Cell reports. Medicine

All 14

Has anakinra been tested in people?

0 of 123 about aging

Yes: 2 trials and 1 observational study in people have been published, and 123 trials are registered.

Approved

  • FDA Kineret

    Nov 14, 2001Arthritis, Rheumatoid, Cryopyrin-Associated Periodic Syndromes, Active Rheumatoid Arthritis, neonatal-onset multisystem inflammatory disease

  • EMA Kineret

    Mar 8, 2002Arthritis, Rheumatoid, COVID-19 virus infection, COVID-19, Cryopyrin-Associated Periodic Syndromes, Familial Mediterranean Fever, arthritis, Still's Disease, Adult-Onset, coronavirus disease 2019, Systemic Juvenile Idiopathic Arthritis, familial cold autoinflammatory syndrome, Muckle-Wells syndrome, periodic fever, neonatal-onset multisystem inflammatory disease, Still's disease

Repurposing

40 of 97

In trials

  • Mucocutaneous Lymph Node Syndrome

    Phase 3Recruiting4 trials

  • Alcoholic hepatitis

    Phase 2/3Results posted1 trial

  • Macrophage activation syndrome

    Phase 2Completed4 trials

  • Lymphoma, large b-cell, diffuse

    Phase 2Results posted2 trials

  • Virus disease

    Phase 2Completed2 trials

  • Respiratory distress syndrome

    Phase 2Status unknown1 trial

All 9

Stopped

  • NCT02236481TerminatedRheumatoid arthritis

    Decision of the Sponsor for Early Benefits

  • NCT04364009TerminatedCOVID-19

    Efficiency and safety reasons

  • NCT03265132TerminatedAdult onset still disease

    Meeting enrolment target (81 pat) will not be feasible within reasonable time.

  • NCT00069329TerminatedCryopyrin-associated periodic syndrome

    data submitted for Food and Drug Administration (FDA) approval

  • NCT02902731TerminatedGiant cell arteritis

    experimental treatment no longer available

  • NCT02930122TerminatedAnterior cruciate ligament injury

    Lack of funding

All 12

Who is developing anakinra?

1 company: Swedish Orphan Biovitrum.

Companies
  • Swedish Orphan BiovitrumPhase 3juvenile onset still disease, adult onset still disease

Trial sponsors

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 1Apr 2026: 0May 2026: 0Jun 2026: 2Jul 2026: 0Aug 2026: 0Sep 2026: 1Oct 2026: 0Nov 2026: 04 papers in 12 months
medRxiv

ASXL1-mutant clonal hematopoiesis links to aortic valve disease

In cohort data and cell models, ASXL1 mutations tracked with incident aortic stenosis and promoted valvular calcification that was reduced by IL-1 or IL-6 inhibition.In cohort data and cell models, ASXL1 mutations tracked with incident aortic stenosis and promoted valvular calcification that was reduced by IL-1 or IL-6 inhibition.

Preprint: cohort study of 449,109 peopleASXL1

See all 13 papers on anakinra